AUTHOR AND EDITOR INFORMATION

Section 1 of 13  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Further Reading
• Acknowledgments
• Multimedia
• References

INTRODUCTION

Section 2 of 13  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Further Reading
• Acknowledgments
• Multimedia
• References

Background

Altitude illness refers to a group of syndromes that result from hypoxia. Acute mountain sickness (AMS) and high-altitude cerebral edema (HACE) are manifestations of the brain pathophysiology, while high-altitude pulmonary edema (HAPE) is that of the lung. Everyone traveling to altitude is at risk, regardless of age, prior medical history, level of physical fitness, or previous altitude experience.

The high altitude environment generally refers to elevations over 1500 m (4900 ft). Moderate altitude, 2000-3500 m (6600-11,500 ft), includes the elevation of many ski resorts. Although arterial oxygen saturation is well maintained at these altitudes, low PO₂ results in mild tissue hypoxia, and altitude illness is common. Very high altitude refers to elevations of 3500-5500 m (11,500-18,000 ft). Arterial oxygen saturation is not maintained in this range, and extreme hypoxemia can occur during sleep, with exercise, or with illness. HACE and HAPE are most common at these altitudes. Extreme altitude is over 5500 m; above this altitude, successful long-term acclimatization is not possible and, in fact, deterioration ensues. Individuals must progressively acclimatize to intermediate altitudes to reach extreme altitude.

Pathophysiology

Acclimatization

Hypoxia is the primary physiological insult on ascent to high altitude. The fraction of oxygen in the atmosphere remains constant (0.21), but the partial pressure of oxygen decreases along with barometric pressure on ascent to altitude. The inspired partial pressure of oxygen (PiO₂) is lower still because of water vapor pressure in the airways. At the altitude of La Paz, Bolivia (4000 m; 13,200 ft), PiO₂ is 86.4 mm Hg, which is equivalent to breathing 12% oxygen at sea level.

The response to hypoxia depends on both the magnitude and the rate of onset of hypoxia. The process of adjusting to hypoxia, termed acclimatization, is a series of compensatory changes in multiple organ systems over differing time courses from minutes to weeks. While the fundamental process occurs in the metabolic machinery of the cell, acute physiologic responses are essential in allowing the cells time to adjust.
 
The most important immediate response of the body to hypoxia is an increase in minute ventilation, triggered by oxygen-sensing cells in the carotid body. Increased ventilation produces a higher alveolar PO_2. Concurrently, a lowered alveolar PCO₂ results in a respiratory alkalosis and so acts as to limit the increase in ventilation. Renal compensation, through excretion of bicarbonate ion, gradually brings the blood pH back toward normal and allows further increase in ventilation. This process, termed ventilatory acclimatization, requires approximately 4 days at a given altitude and is greatly enhanced by acetazolamide. Patients with inadequate carotid body response (genetic or acquired, eg, after surgery or radiation) or pulmonary or renal disease may have an insufficient ventilatory response and thus not adapt well to high altitude.

In addition to ventilatory changes, circulatory changes occur that increase the delivery of oxygen to the tissues. Ascent to high altitude initially results in increased sympathetic activity, leading to increased resting heart rate and cardiac output and mildly increased blood pressure. The pulmonary circulation reacts to hypoxia with vasoconstriction. This may improve ventilation/perfusion matching and gas exchange, but the resulting pulmonary hypertension can lead to a number of pathological syndromes at high altitude, including HAPE and altitude-related right heart failure. Cerebral blood flow increases immediately on ascent to high altitude, returning to normal over about a week. The magnitude of the increase varies but averages 24% at 3810 m and more at higher altitude. Whether the headache of AMS is related to this flow increase is not known.

Hemoglobin concentration increases after ascent to high altitude, increasing the oxygen-carrying capacity of the blood. Initially, it increases due to hemoconcentration from a reduction in plasma volume secondary to altitude diuresis and fluid shifts. Subsequently, over days to months, erythropoietin stimulates increased red cell production. In addition, the marked alkalosis of extreme altitude causes a leftward shift of the oxyhemoglobin dissociation curve, facilitating loading of the hemoglobin with oxygen in the pulmonary capillary.

Sleep architecture is altered at high altitude, with frequent arousals and nearly universal subjective reports of disturbed sleep. This generally improves after several nights at a constant altitude, though periodic breathing (Cheyne-Stokes) is normal above 2700 m.

Pathophysiology of HAPE

HAPE is a noncardiogenic, hydrostatic pulmonary edema, characterized by pulmonary hypertension and increased pulmonary capillary pressure. Left ventricular function is normal in HAPE. Patchy hypoxic pulmonary vasoconstriction and consequent localized overperfusion, combined with hypoxic permeability of pulmonary capillary walls, results in a high-pressure, high-permeability leak. In addition, alveolar fluid clearance may be altered in those susceptible to HAPE.

Hypoxic pulmonary vasoconstriction results in increased pulmonary artery pressures in all who ascend to high altitude, but it is exaggerated in those susceptible to HAPE, primarily due to genetically determined factors. This genetically based individual susceptibility is perhaps the greatest risk factor, although preexisting medical conditions associated with pulmonary hypertension or a restricted pulmonary vascular bed will greatly increase susceptibility to HAPE. Exercise increases the risk of HAPE because it increases cardiac output, severity of hypoxemia, and pulmonary artery pressure at altitude.

While it has long been held that HAPE and AMS/HACE do not share pathophysiologic basis, recent studies have noted increases in optic nerve sheath diameter (ONSD)—a measure of increased intracranial pressure—in patients with acute HAPE, which decreased as HAPE resolved. 

Frequency

United States

The true incidence is unknown, although HAPE is known to occur at high-altitude ski areas in Colorado at a rate of approximately 1 case per 10,000 skier-days. 

Current research with the International HAPE Registry is working to better define the incidence and factors surrounding HAPE occurrence.

International

The reported incidence of HAPE varies from 0.01-15%, depending on the altitude, the ascent rate, and the population at risk.

Mortality/Morbidity

HAPE can be rapidly fatal within a few hours unless treated by descent or oxygen. HAPE is the most common cause of death related to high altitude.

Given appropriate treatment, recovery from HAPE is usually complete and can occur rapidly (1-2 d). This noted, even with proper treatment, a small percentage of patients will die. Patients who recover have rapid clearing of edema fluid and do not develop fibrosis or other long-term sequelae.

A recent report describes a case series of HAPE treated successfully at more than 14,000 ft when emergent descend was not a viable option. Importantly, while these cases had good outcomes, they were being treated by physicians with expertise in treating HAPE who had full access to advanced treatment modalities. Rapid descent remains a critical treatment for most cases of HAPE.

Race

Prior reports of "genetic protection" from HAPE afforded to Tibetan and Sherpa peoples must be taken as limited in scope and may well not be true. Case series of patients with HAPE from indigenous groups previously reported as "protected" from HAPE exist.

Sex

Some studies have suggested that males are affected more frequently than females; however, these studies were retrospective and did not study the population at risk.

Age

Occurrence of primary HAPE has no clear association with age, although reascent HAPE is more common in children who reside in high altitude who return to high altitudes after a lowland sojourn than in adults in the same circumstances.

CLINICAL

Section 3 of 13  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Further Reading
• Acknowledgments
• Multimedia
• References

History

HAPE generally occurs 2-4 days after ascent to high altitude, often worsening at night. Decreased exercise performance is the earliest symptom, usually associated with a dry cough. The early course is subtle; as the illness progresses, the cough worsens and becomes productive; dyspnea can be severe, tachypnea and tachycardia develop, and drowsiness or other CNS symptoms may develop. Chest radiographs characteristically show patchy unilateral or bilateral fluffy infiltrates and a normal cardiac silhouette. The presence of a low-grade fever has led to misdiagnosis as pneumonia and to subsequent deaths.

HAPE varies in severity from mild to immediately life-threatening. It can be fatal within a few hours, and it is the most common cause of death related to high altitude. Differential diagnosis is sometimes problematic, but HAPE improves dramatically with descent or oxygen, whereas other diagnoses do not; these should be pursued in patients who do not fit this pattern.

The Lake Louise Consensus definition of HAPE requires at least 2 of the following symptoms (in the context of a recent elevation gain):

• Weakness or decreased exercise
• Cough
• Dyspnea at rest
• Chest tightness or congestion

Physical

• In addition to 2 symptoms, the Lake Louise Consensus definition of HAPE requires at least 2 of the following signs:
• • Rales or wheezing in at least one lung field
  • Central cyanosis or arterial oxygen desaturation relative to altitude
  • Tachycardia
  • Tachypnea
• Fever and orthopnea are commonly present in HAPE; pink/frothy sputum is a late finding in severe HAPE.

Causes

• Rapid ascent
• Higher altitudes are more risky.
• Low hypoxic ventilatory response
• Congenital absence of a pulmonary artery or other vascular abnormalities that create a restricted pulmonary circulatory bed
• Pulmonary hypertension
• Physical exertion may precipitate or exacerbate HAPE (by raising pulmonary artery pressures).

DIFFERENTIALS

Section 4 of 13  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Further Reading
• Acknowledgments
• Multimedia
• References

WORKUP

Section 5 of 13  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Further Reading
• Acknowledgments
• Multimedia
• References

Lab Studies

• Use Gram stain or culture to evaluate for cases requiring antibiotic therapy.

Imaging Studies

• Chest radiography
• • The chest radiograph is usually irrelevant to field diagnosis and management but is useful in the context of a high-altitude clinic or hospital.
  • Patchy, asymmetric, unilateral or bilateral fluffy infiltrates and a normal cardiac silhouette are characteristic of HAPE.
• Thoracic ultrasonography (comet tail sign)
• • Recent reports reveal thoracic ultrasonographic assessment for comet tail signs to be sensitive in making the diagnosis of HAPE and grading clinical severity.¹
  • Standard thoracic ultrasonography uses 28 standard views across the anterior chest and can be completed in minutes.
  • Comet tail signs are artifacts resulting from increased pulmonary edema.
  • Advantages of ultrasonography include portability of equipment, use of nonionizing radiation, rapidity of assessment, and ease of reassessment.
  • Current studies are ongoing to define sensitivity and rate of response of ultrasonography versus standard radiography.

Other Tests

• Pulse oximetry
• • Although unnecessary for diagnosis, pulse oximetry is very helpful for in-the-field differentiation of HAPE, high-altitude cough, and other less serious respiratory problems.
  • HAPE demonstrates arterial oxygen desaturation relative to normal for the altitude at which measurement is made.

TREATMENT

Section 6 of 13  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Further Reading
• Acknowledgments
• Multimedia
• References

Prehospital Care

The mainstay of treatment is descent for anything other than mild HAPE. Descent to an altitude below that where symptoms started is always effective treatment, but it may not be practical or possible given the topography, weather, the patient's ultimate trekking or climbing goals, or group resources. Accordingly, a descent of 500-1000 m is usually sufficient. As noted above, while case series of treatment of even severe HAPE under expert care in well-equipped settings have been reported, descent for other than mild HAPE cases remains clearly indicated. Selected cases of reascent HAPE and mild HAPE at moderate altitude may be treated with oxygen and strict bedrest. If patients worsen, they must descend.

All of the following treatments are used as an adjunct to descent. Oxygen, if available, is lifesaving and should be administered at 4 L/min by mask or nasal cannula. Nifedipine should be used if descent or oxygen is not available. Nifedipine may help prevent exertional worsening in patients being evacuated on foot. Portable hyperbaric chambers can effect a physiologic (simulated) descent when actual descent is not possible or practical. End-positive pressure masks are useful in treating HAPE but are poorly tolerated.

The role of acetazolamide in the treatment of HAPE remains ill-defined but may prove beneficial. Additionally, recent reports give evidence that dexamethasone might have beneficial effect in HAPE as well. While not clearly established, there is little apparent downside risk to using either acetazolamide and dexamethasone in severe HAPE.

Inhaled salmeterol (a beta-agonist) has been demonstrated to help prevent acute HAPE in HAPE-susceptible populations. Salmeterol is thought to act by increasing alveolar fluid clearance through pulmonary sodium channels. Although its use in HAPE treatment has not been proven, it is often used in this indication.

Phosphodiesterase inhibitors have also been demonstrated to help prevent acute HAPE in HAPE-susceptible populations. These agents are thought to act by increasing availability of nitric oxide in pulmonary arterial vessels and so result in decreased pulmonary arterial tone and reduced pulmonary hypertension. Although its use in HAPE treatment has not been proven, it is often used in this indication.

Only limited studies provide any evidence that furosemide may be useful with acute HAPE, and it is not without downside risk. Furosemide should be used with substantial caution, if at all, as many patients are intravascularly depleted. Most authors discourage use of furosemide in treating HAPE.

Portable hyperbaric chambers (eg, Gamow, CERTEC, PAC) are widely used among adventure travel/trekking groups and climbing expeditions. These chambers are lightweight, coated fabric bags about 2 m in length and 0.7 m in diameter. The patient is placed inside the bag, which is sealed shut and inflated with a manually operated pump, pressurizing the inside to 105-220 mm Hg above ambient atmospheric pressure. This pressure gradient is regulated by pop-off valves set to the target pressure, and it is fixed depending on the brand of bag in use.

Depending on the elevation, a physiologic (simulated) descent of about 2000 m (7000 ft) may be achieved within minutes. Intermittent pumping is necessary to flush carbon dioxide from the system, unless a chemical scrubber system is used. Patients with severe HAPE may need to have their head elevated to tolerate lying down. Elevation can be accomplished by placing the bag on a rigid surface, such as boards or a wooden bed, and propping up the head end by 0.3-0.5 m (12-20 inches).

In practice, most patients with moderate HAPE tolerate lying flat after reaching the physiologic lower elevation of the pressurized bag. Patients typically are treated in 1-hour increments and then are reevaluated, with additional treatments as indicated. Closely monitor patients for rebound signs and symptoms, which may occur soon after removal from the hyperbaric environment, or they may develop over a period of hours.

Emergency Department Care

• For cases of persistent desaturation or dyspnea, administer oxygen to keep oxygen saturation (SaO₂) above 90%.
• Consider continuing nifedipine in symptomatic patients.
• Furthermore, consider dexamethasone, phosphodiesterase inhibitors, and inhaled beta-agonist as conditions indicate.
• Emergency departments at altitude must assess the elevation at which the patient's illness occurred and determine whether further descent is necessary.

Consultations

Children living at altitude who develop HAPE should undergo screening for diagnosis of underlying cardiopulmonary abnormalities, including pulmonary hypertension.

MEDICATION

Section 7 of 13  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Further Reading
• Acknowledgments
• Multimedia
• References

Treatment of HAPE is indicated upon diagnosis. High-altitude cough may be treated when the symptoms become severe enough to interfere with the individual's activities.

Drug Category: Calcium channel blockers

Nifedipine is used for its pulmonary vasodilative effects. It inhibits calcium ions from entering the slow channels or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation.

Drug Category: Phosphodiesterase (type 5) enzyme inhibitor

This agent acts to increase available nitric oxide in pulmonary arterial vessels, resulting in vessel relaxation and decreased pulmonary hypertension. It has been found effective for HAPE prophylaxis in HAPE-susceptible patients.

Drug Category: Corticosteroid

Exact mechanism has not yet been well defined but has been found effective for HAPE prophylaxis in HAPE-susceptible patients.

Drug Category: Beta agonists

Sodium-dependent absorption of liquid from the airways may be defective in persons who are susceptible to HAPE; beta-adrenergic agents up-regulate the clearance of alveolar fluid.

Drug Category: Carbonic anhydrase inhibitors

These agents are possibly beneficial in the prophylaxis of HAPE.

Drug Category: Antitussives

These agents are used for the symptomatic treatment of high-altitude cough.

Drug Category: Analgesics

These agents are indicated for the treatment of mild to moderate pain and headache.

FOLLOW-UP

Section 8 of 13  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Further Reading
• Acknowledgments
• Multimedia
• References

Further Inpatient Care

• Admission criteria are as follows:
• • Significant arterial oxygen desaturation at rest
  • Dyspnea at rest
  • Inability to descend
• Treatment of moderate-to-severe HAPE after descent consists of bedrest and oxygen; continuation of nifedipine, tadalafil, dexamethasone, inhaled beta-agonist also may be helpful.
• Discharge criteria are as follows:
• • Normal SaO₂ on room air
  • No dyspnea at rest (mild dyspnea with exertion may persist for several days)

Further Outpatient Care

• Outpatient treatment of mild HAPE after descent consists of bedrest. Follow up in 24 hours to check on clearance of HAPE edema.

Deterrence/Prevention

• Recommendations on staged ascents are by and large adequate for the average person, but some persons will still become ill despite a slow, staged ascent. Persons traveling to high altitude should allow adequate time for acclimatization and pay careful attention to symptoms. Helpful guidelines to avoid altitude illness include the following:
• • Avoid abrupt ascent to sleeping elevations over 3000 m (10,000 ft).
  • Spend 1-2 nights at an intermediate elevation (2500-3000 m) before further ascent.
  • Above 3000 m, sleeping elevations should not increase by more than 300-400 m per night.
  • When topography or village locations dictate more rapid ascent, or after every 1000 m gained, spend a second night at the same elevation.
  • Day hikes to higher elevations, with return to lower sleeping elevations help to improve acclimatization.
  • Avoid overexertion.
  • Avoid alcohol consumption in the first 2 days at a new, higher elevation; in addition to concerns about respiratory depression and exaggerated sleep hypoxemia, an AMS headache the next morning is all too easily dismissed as a hangover.
• Significant abnormalities of pulmonary vasculature (eg, absence of the left pulmonary artery) or pulmonary hypertension are contraindications for going to high altitude.
• The indication for chemoprophylaxis of HAPE is repeated episodes. Whether one prior episode should encourage prophylaxis is arguable, but demonstrated susceptibility certainly requires caution. Oftentimes, a slower ascent is the only preventive method required. Effective agents for prevention of HAPE include nifedipine and salmeterol. Those with a history of HAPE should carry nifedipine to use either prophylactically or with the first signs of HAPE. Salmeterol reduced HAPE by 50% in susceptible persons, appears safe, and should be considered for treatment as well, though it has not yet been studied for this indication. Recent studies have shown evidence for a prophylactic role in HAPE for dexamethasone, but detailed study of optimal dosing protocol has not been reported. Oral phosphodiesterase-5 inhibitors (eg, sildenafil, tadalafil) have been found effective for prophylaxis of HAPE, but they have not yet been studied for treatment.

Complications

• Secondary pulmonary infections may occur. Note that a productive cough while recovering from HAPE is common. Use Gram stain or culture to evaluate for cases requiring antibiotic therapy.

Prognosis

• The prognosis is excellent for survivors, with rapid clearing of the edema fluid and no long-term sequelae. Patients may need from 3 days to 2 weeks to recover completely; after all symptoms have resolved, cautious reascent is acceptable.

Patient Education

• It is recommended that all HAPE cases be reported immediately to the International HAPE Registry. This Registry is owned by physician/scientists of the International Society of Mountain Medicine and seeks to improve HAPE prevention and care. 
• Patients should be educated on staged ascents (see Deterrence/Prevention).
• The golden rules of altitude illness are as follows:
• • If a person feels sick at altitude, his or her condition is altitude illness unless proven otherwise.
  • If symptoms of acute mountain sickness (AMS) are present, go no higher.
  • If symptoms are worsening, fail to improve with treatment, or if HACE or HAPE is present, descend immediately.
• For excellent patient education resources, visit eMedicine's Environmental Exposures and Injuries. Also, see eMedicine's patient education article Mountain Sickness.

MISCELLANEOUS

Section 9 of 13  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Further Reading
• Acknowledgments
• Multimedia
• References

Medical/Legal Pitfalls

• Many lawsuits have been brought over missed diagnoses and deaths.
• • HAPE misdiagnosed as pneumonia
  • Pneumonia misdiagnosed as HAPE
  • Pulmonary embolism misdiagnosed as HAPE
  • Congestive heart failure (CHF)/myocardial infarction (MI) misdiagnosed as HAPE
  • Failure to recognize pulmonary vascular abnormalities as a contraindication to high-altitude travel

Special Concerns

• HAPE generally improves dramatically with descent; another diagnosis should be pursued in patients who do not fit this history.
• Pulmonary embolism has been reported in young, otherwise healthy persons at high altitude. This diagnosis should be considered particularly in extreme altitude climbers, who may be at increased risk due to dehydration, polycythemia, and periods of tent-bound inactivity.
• High-altitude cough is common, increases with elevation, and is a significant cause of morbidity among extreme-altitude climbers. The cough is paroxysmal and sometimes sufficiently forceful to fracture ribs. Sputum is frequently purulent, but fever is absent. Normal exercise performance, lack of dyspnea at rest, and absence of rales or cyanosis help distinguish high-altitude cough from HAPE. A concurrent sore throat is common, without any abnormal findings on examination. The cause of high-altitude cough is unknown but is probably multifactorial, including mucosal injury from hyperventilation of cold, dry air; airway inflammation; hypoxic bronchoconstriction; and alteration in the cough threshold. No convincing evidence of an infectious etiology exists. Treatment is symptomatic with cough suppressants; airway warming and hydration by breathing through a mask or a scarf may be helpful in both prevention and treatment.

FURTHER READING

Section 10 of 13  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Further Reading
• Acknowledgments
• Multimedia
• References

International HAPE Registry

ACKNOWLEDGMENTS

Section 11 of 13  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Further Reading
• Acknowledgments
• Multimedia
• References

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Thomas E Dietz, MD, to the development and writing of this article.

MULTIMEDIA

Section 12 of 13  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Further Reading
• Acknowledgments
• Multimedia
• References

Media file 1:  High-altitude pulmonary edema (HAPE). Image courtesy Dr Peter Hackett.
	View Full Size Image
Media type:  Radiograph

Media file 2:  Hyperbaric treatment at 4250 m in a Gamow bag.
	View Full Size Image
Media type:  Photo

Media file 3:  Thoracic ultrasonography: comet tail sign. Patient with acute high-altitude pulmonary edema (HAPE). Note wedge-shaped forms extending from pleural lining. In contrast, normal thoracic sonogram (below) reveals only diffuse, "snow storm" appearance. Courtesy of Dr Peter Fagenholz, et al.
	View Full Size Image
Media type:  Ultrasound

Media file 4:  Thoracic ultrasonography. Normal thoracic sonogram reveals only diffuse, "snow storm" appearance without comet tail sign. Courtesy of Dr Peter Fagenholz, et al.
	View Full Size Image
Media type:  Ultrasound

REFERENCES

Section 13 of 13

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Further Reading
• Acknowledgments
• Multimedia
• References

1. Fagenholz PJ, Gutman JA, Murray AF, et al. Chest ultrasonography for the diagnosis and monitoring of high-altitude pulmonary edema. Chest. Apr 2007;131(4):1013-8. [Medline].
2. Bartsch P, Maggiorini M, Ritter M, et al. Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med. Oct 31 1991;325(18):1284-9. [Medline].
3. Bartsch P, Mairbaurl H, Maggiorini M, et al. Physiological aspects of high-altitude pulmonary edema. J Appl Physiol. Mar 2005;98(3):1101-10. [Medline].
4. Clarenbach CF, Christ AL, Senn O, et al. Dexamethasone and tadalafil prevent HAPE and subclinical alterations in lung function and nocturnal oxygenation associated with pulmonary interstitial fluid accumulation. High Alt Med Biol. 2004;4:478.
5. Das BB, Wolfe RR, Chan KC, et al. High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude. Arch Pediatr Adolesc Med. Dec 2004;158(12):1170-6. [Medline].
6. Durmowicz AG. Pulmonary edema in 6 children with Down syndrome during travel to moderate altitudes. Pediatrics. Aug 2001;108(2):443-7. [Medline].
7. Fagenholz PJ, Gutman JA, Murray AF, et al. Evidence for increased intracranial pressure in high altitude pulmonary edema. High Alt Med Biol. Winter 2007;8(4):331-6. [Medline].
8. Fagenholz PJ, Gutman JA, Murray AF, et al. Treatment of high altitude pulmonary edema at 4240 m in Nepal. High Alt Med Biol. Summer 2007;8(2):139-46. [Medline].
9. Hackett PH. High-altitude medicine. In: Auerbach PS, ed. Wilderness Medicine. 4^th ed. St. Louis, Mo: Mosby; 2001:2-43.
10. Hackett PH, Oelz O. The Lake Louise consensus on the definition and quantification of altitude illness. In: Sutton J, Coates G, Houston C, eds. Hypoxia and Mountain Medicine. 1992:327-30.
11. Hackett PH, Roach RC. High altitude cerebral edema. High Alt Med Biol. Summer 2004;5(2):136-46. [Medline].
12. Hackett PH, Roach RC. High-altitude illness. N Engl J Med. Jul 12 2001;345(2):107-14. [Medline].
13. Harris NS, Stephen TH, Hackett P. International high altitude pulmonary edema registry: research tools for the new millinneum. High Alt Med Biol. 2004;5(2):221.
14. Houston CS. Acute pulmonary edema of high altitude. N Engl J Med. Sep 8 1960;263:478-80. [Medline].
15. Hultgren HN. High-altitude pulmonary edema: current concepts. Annu Rev Med. 1996;47:267-84. [Medline].
16. Jean D, Leal C, Kriemler S, et al. Medical recommendations for women going to altitude. High Alt Med Biol. 2005;6(1):22-31. [Medline].
17. Maggiorini M, Brunner-La Rocca H-P, Bihm T, et al. Phosphodiesterase-5 inhibition and glucocorticoids prevent excessive hypoxic pulmonary vasoconstriction and high altitude pulmonary edema in susceptible subjects. High Alt Med Biol. 2004;4:494.
18. Maggiorini M, Brunner-La Rocca HP, Peth S, Fischler M, Böhm T, Bernheim A, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med. Oct 3 2006;145(7):497-506. [Medline].
19. Nakagawa S, Kubo K, Koizumi T, et al. High-altitude pulmonary edema with pulmonary thromboembolism. Chest. Mar 1993;103(3):948-50. [Medline].
20. Oelz O, Maggiorini M, Ritter M, et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. Int J Sports Med. Oct 1992;13 Suppl 1:S65-8. [Medline].
21. Pollard AJ, Niermeyer S, Barry P, et al. Children at high altitude: an international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001. High Alt Med Biol. Fall 2001;2(3):389-403. [Medline]. [Full Text].
22. Richalet JP, Gratadour P, Robach P, et al. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med. Feb 1 2005;171(3):275-81. [Medline].
23. Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med. May 23 2002;346(21):1631-6. [Medline].
24. Schoene RB. Fatal high altitude pulmonary edema associated with absence of the left pulmonary artery. High Alt Med Biol. Fall 2001;2(3):405-6. [Medline].
25. Schoene RB. Unraveling the mechanism of high altitude pulmonary edema. High Alt Med Biol. Summer 2004;5(2):125-35. [Medline].
26. Schoene RB, Hackett PH, Henderson WR, et al. High-altitude pulmonary edema. Characteristics of lung lavage fluid. JAMA. Jul 4 1986;256(1):63-9. [Medline].
27. Shlim DR, Papenfus K. Pulmonary embolism presenting as high-altitude pulmonary edema. Wilderness Environ Med. May 1995;6(2):220-4. [Medline].
28. Swenson ER, Maggiorini M, Mongovin S, et al. Pathogenesis of high-altitude pulmonary edema: inflammation is not an etiologic factor. JAMA. May 1 2002;287(17):2228-35. [Medline].
29. Taber R. Protocols for the use of a portable hyperbaric chamber for the treatment of high altitude disorders. J Wilderness Med. 1990;1:181-92.
30. West JB. The physiologic basis of high-altitude diseases. Ann Intern Med. Nov 16 2004;141(10):789-800. [Medline].
31. West JB, Colice GL, Lee YJ, et al. Pathogenesis of high-altitude pulmonary oedema: direct evidence of stress failure of pulmonary capillaries. Eur Respir J. Apr 1995;8(4):523-9. [Medline].
32. Zafren K, Reeves JT, Schoene R. Treatment of high-altitude pulmonary edema by bed rest and supplemental oxygen. Wilderness Environ Med. May 1996;7(2):127-32. [Medline].

Article Last Updated: Aug 4, 2008